Javascript must be enabled to continue!
Novel GVHD resistant humanized-PBMC mouse model for preclinical HIV research
View through CrossRef
Abstract
Humanized mouse models are based on the engraftment of human cells in immunodeficient mouse strains, most notably the NSG strain. Most used models have a major limitation in common, the development of graft-versus-host disease (GVHD). GVHD not only introduces variabilities into the research data but also leads to animal welfare concerns. A new mouse strain, B6.129S-Rag2
tm1Fwa
CD47
tm1Fpl
Il2rg
tm1Wjl
/J which lacks Rag1, IL2rg, and CD47 (triple knockout or TKO), is resistant to GVHD development. We transplanted TKO mice with human peripheral blood mononuclear cells (PBMCs) to establish a new humanized PBMC (hu-PBMC) mouse model. A cohort of these mice was infected with HIV-1 and monitored for plasma HIV viremia and CD4
+
T cell depletion. The onset and progression of GVHD were monitored by clinical signs. This study demonstrates that TKO mice transplanted with human PBMCs support engraftment of human immune cells in primary and secondary lymphoid tissues, rectum, and brain. Moreover, the TKO hu-PBMC model supports HIV-1 infection via intraperitoneal, rectal, or vaginal routes, as confirmed by robust plasma HIV viremia and CD4
+
T cell depletion. Lastly, TKO mice showed a delayed onset of GVHD clinical signs (∼21 days) and exhibited significant decreases in plasma levels of TNFβ. Based on these results, the TKO hu-PBMC mouse model not only supports humanization and HIV-1 infection but is also resistant to GVHD development, making this model a valuable tool in HIV research.
Importance
Currently, there is no cure or vaccine for HIV infection, thus continued research is needed to end the HIV pandemic. While many animal models are used in HIV research, none is used more than the humanized mouse model. A major limitation with current humanized mouse models is the development of graft-versus-host disease (GVHD). Here, we show a novel humanized mouse model that is resistant to GVHD development and supports and models HIV infection comparable to well-established humanized mouse models.
Title: Novel GVHD resistant humanized-PBMC mouse model for preclinical HIV research
Description:
Abstract
Humanized mouse models are based on the engraftment of human cells in immunodeficient mouse strains, most notably the NSG strain.
Most used models have a major limitation in common, the development of graft-versus-host disease (GVHD).
GVHD not only introduces variabilities into the research data but also leads to animal welfare concerns.
A new mouse strain, B6.
129S-Rag2
tm1Fwa
CD47
tm1Fpl
Il2rg
tm1Wjl
/J which lacks Rag1, IL2rg, and CD47 (triple knockout or TKO), is resistant to GVHD development.
We transplanted TKO mice with human peripheral blood mononuclear cells (PBMCs) to establish a new humanized PBMC (hu-PBMC) mouse model.
A cohort of these mice was infected with HIV-1 and monitored for plasma HIV viremia and CD4
+
T cell depletion.
The onset and progression of GVHD were monitored by clinical signs.
This study demonstrates that TKO mice transplanted with human PBMCs support engraftment of human immune cells in primary and secondary lymphoid tissues, rectum, and brain.
Moreover, the TKO hu-PBMC model supports HIV-1 infection via intraperitoneal, rectal, or vaginal routes, as confirmed by robust plasma HIV viremia and CD4
+
T cell depletion.
Lastly, TKO mice showed a delayed onset of GVHD clinical signs (∼21 days) and exhibited significant decreases in plasma levels of TNFβ.
Based on these results, the TKO hu-PBMC mouse model not only supports humanization and HIV-1 infection but is also resistant to GVHD development, making this model a valuable tool in HIV research.
Importance
Currently, there is no cure or vaccine for HIV infection, thus continued research is needed to end the HIV pandemic.
While many animal models are used in HIV research, none is used more than the humanized mouse model.
A major limitation with current humanized mouse models is the development of graft-versus-host disease (GVHD).
Here, we show a novel humanized mouse model that is resistant to GVHD development and supports and models HIV infection comparable to well-established humanized mouse models.
Related Results
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
Abstract
Introduction
Human immunodeficiency virus (HIV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) surface glycoproteins, including shared epitope motifs, sho...
Incidence and Risk Factors Associated with Fatal Graft Vs Host Disease after Solid Organ Transplantation in United Network of Organ Transplant Database
Incidence and Risk Factors Associated with Fatal Graft Vs Host Disease after Solid Organ Transplantation in United Network of Organ Transplant Database
Abstract
INTRODUCTION
Graft vs host disease (GVHD) is a rare complication after solid organ transplantation ( ̴ 1-2% with liver and ̴ 5.6% with intest...
Capítulo 6 – HIV-AIDS, como tratar, o que fazer e o que não fazer durante o tratamento?
Capítulo 6 – HIV-AIDS, como tratar, o que fazer e o que não fazer durante o tratamento?
A infecção pelo vírus do HIV pode ocorrer de diversas maneiras, tendo sua principal forma a via sexual por meio do sexo desprotegido. O vírus do HIV fica em um período de incubação...
Initiation of Acute Graft-Versus-Host Disease By Angiogenesis
Initiation of Acute Graft-Versus-Host Disease By Angiogenesis
Abstract
Angiogenesis and inflammation are two closely related processes and inhibition of angiogenesis can ameliorate inflammatory diseases by reducing the recruitm...
Sirolimus, Tacrolimus and Low-Dose Methotrexate Based Graft-Versus-Host Disease (GVHD) Prophylaxis After Non-Ablative or Reduced Intensity Conditioning in Related and Unrelated Donor Allogeneic Stem Cell Transplantation: Decreased Severe Early aGVHD but P
Sirolimus, Tacrolimus and Low-Dose Methotrexate Based Graft-Versus-Host Disease (GVHD) Prophylaxis After Non-Ablative or Reduced Intensity Conditioning in Related and Unrelated Donor Allogeneic Stem Cell Transplantation: Decreased Severe Early aGVHD but P
Abstract
Abstract 4194
Background:
The morbidity and mortality associated with acute and chronic graft-versus-hos...
Abstract 1650: Humanized mouse models for preclinical evaluation of novel immune cell therapies, checkpoint inhibitors, and immune cell engagers
Abstract 1650: Humanized mouse models for preclinical evaluation of novel immune cell therapies, checkpoint inhibitors, and immune cell engagers
Abstract
Background The preclinical evaluation of novel immune therapies demands humanized mouse models with functional human immune cells. In previous studies we ha...
A Phase II Study of Tacrolimus and Thymoglobulin, As Graft-Versus-Host-Disease Prophylaxis in Patients Undergoing Related Donor Allogeneic Hematopoietic Cell Transplantation
A Phase II Study of Tacrolimus and Thymoglobulin, As Graft-Versus-Host-Disease Prophylaxis in Patients Undergoing Related Donor Allogeneic Hematopoietic Cell Transplantation
Abstract
A Phase II study of Tacrolimus and Thymoglobulin, as Graft-Versus-Host-Disease Prophylaxis in Patients Undergoing Related Donor Allogeneic Hematopoietic Cel...
Laboratory-based Evaluation of Wondfo HIV1/2 Rapid Test Kits in the Gambia, December 2020
Laboratory-based Evaluation of Wondfo HIV1/2 Rapid Test Kits in the Gambia, December 2020
Background: HIV rapid diagnosis in The Gambia is mainly done using Determine HIV-1/2 and First Response HIV 1.2.0 or SD Bioline HIV-1/2 3.0 for screening and sero-typing of HIV res...

